#JPM24 quick hits: A 'great year for M&A'; an optimistic Sarepta; Pfizer's CEO + more
SAN FRANCISCO — The dealmaking on the first day of the JP Morgan Healthcare Conference once again served as a barometer for an industry that’s been dragged down by what Flagship Pioneering founder Noubar Afeyan describes as a “polycrisis” of wars, politics and weakened trust.
But it’s not all bad news! We saw some interesting deals emerge on Monday. Merck is spending $680 million to buy Harpoon Therapeutics, Novartis licensed two cardiovascular RNAi drugs from Shanghai Argo Biopharmaceutical for $185 million upfront, and Johnson & Johnson bought antibody-drug conjugate developer Ambrx Biopharma for $2 billion in cash.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.